Equities analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings per share of ($0.89) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.29) to ($0.68). Sarepta Therapeutics posted earnings per share of ($1.18) during the same quarter last year, which would indicate a positive year-over-year growth rate of 24.6%. The company is scheduled to report its next quarterly earnings results on Thursday, October 26th.

On average, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($0.97). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.73) per share, with EPS estimates ranging from ($2.91) to ($0.39). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the previous year, the company posted ($1.19) earnings per share. The company’s quarterly revenue was up 350000.0% compared to the same quarter last year.

A number of brokerages have weighed in on SRPT. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. Janney Montgomery Scott lifted their price target on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research note on Monday, July 24th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $96.00 target price (down previously from $102.00) on shares of Sarepta Therapeutics in a research report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $61.28.

In other news, SVP Alexander Cumbo sold 5,918 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandesh Mahatme sold 50,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the sale, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The disclosure for this sale can be found here. Insiders have sold a total of 78,056 shares of company stock worth $3,224,208 over the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Baird Financial Group Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter worth $223,000. Teachers Advisors LLC boosted its position in Sarepta Therapeutics by 190.1% in the fourth quarter. Teachers Advisors LLC now owns 222,786 shares of the biotechnology company’s stock worth $6,111,000 after buying an additional 146,002 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Sarepta Therapeutics by 39.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,236 shares of the biotechnology company’s stock worth $333,000 after buying an additional 3,173 shares during the period. Camber Capital Management LLC bought a new position in Sarepta Therapeutics during the first quarter worth approximately $39,960,000. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in Sarepta Therapeutics by 34.7% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 14,659 shares of the biotechnology company’s stock worth $434,000 after buying an additional 3,774 shares during the period. Institutional investors own 63.11% of the company’s stock.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 0.52% during midday trading on Friday, hitting $36.51. The stock had a trading volume of 1,003,697 shares. The firm’s market cap is $2.35 billion. Sarepta Therapeutics has a 52-week low of $25.47 and a 52-week high of $63.73. The firm’s 50 day moving average price is $37.58 and its 200 day moving average price is $33.27. Sarepta Therapeutics also saw some unusual options trading activity on Tuesday. Investors acquired 11,628 call options on the company. This represents an increase of approximately 595% compared to the average volume of 1,672 call options.

WARNING: “Zacks: Analysts Anticipate Sarepta Therapeutics, Inc. (SRPT) Will Announce Earnings of -$0.89 Per Share” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/25/zacks-analysts-anticipate-sarepta-therapeutics-inc-srpt-will-announce-earnings-of-0-89-per-share.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.